XOMA 629

Drug Profile

XOMA 629

Alternative Names: 0.1% XMP 629 acetate gel; XMP 629; XMP.629 peptide; XOMA-629

Latest Information Update: 26 Nov 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator XOMA
  • Class Antiacnes; Antibacterials; Antifungals
  • Mechanism of Action Endotoxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Bacterial infections; Impetigo
  • Discontinued Acne; Mycoses

Most Recent Events

  • 24 Jul 2008 Phase-II clinical trials in Impetigo in USA (Topical)
  • 14 May 2008 Preclinical trials in Bacterial infections in USA (unspecified route)
  • 07 Sep 2006 XOMA is conducting preclinical optimisation studies of a reformulated topical XOMA 629 product for the treatment of mild-to-moderate acne in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top